FMP
Nanobiotix S.A.
NBTX
NASDAQ
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
3.39 USD
0.18 (5.31%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
56.77k
11.35k
5.42M
41.11M
-13.18M
-13.84M
-14.53M
-15.26M
-16.02M
-16.82M
-
-80
47.66k
658.12
-132.06
5
5
5
5
-35.76M
-51.78M
-51.26M
-26.89M
-66.22M
7.35M
7.71M
8.1M
8.5M
8.93M
-62.99k
-456.05k
-945.37
-65.42
502.4
-53.08
-53.08
-53.08
-53.08
-37.75M
-53.55M
-52.96M
-27.52M
-68.06M
7.39M
7.76M
8.15M
8.55M
8.98M
-66.5k
-471.65k
-976.78
-66.94
516.37
-53.39
-53.39
-53.39
-53.39
1.99M
1.77M
1.7M
625.57k
1.84M
-6.06M
-6.36M
-6.68M
-7.02M
-7.37M
3.51k
15.6k
31.41
1.52
-13.96
43.79
43.79
43.79
43.79
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)